BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout

2026-05-06 11:29:00

SynAct Pharma announced this morning that the last patient has completed dosing in the phase IIb ADVANCE study, the company's pivotal trial of resomelagon (AP1189) in newly diagnosed rheumatoid arthritis. With dosing now closed across more than 30 sites, attention shifts to the topline readout, which the company continues to expect in June 2026.

Read the full article at biostock.se:

SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Vem äger bolaget?

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden